Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Secondary Clear all

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension Secondary, Heart Failure
Interventions: Sodium Nitrite, Placebo Oral Capsule; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
Interventions: Goniotomy; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Head Injury
Interventions: Place HOB in alternate positions from 0-50 degrees.; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Aliskiren, Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Nitric Oxide, INO Pulse - NO Delivery System; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Geno LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more

Conditions: Cardiovascular Phenotype, Metabolic Phenotype, Hypertensive Disease, Psychological Phenotype, Audio
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 99 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions: Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant; Drug · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan, Matching Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more

Conditions: Stroke, Hypertension
Interventions: Primary Care Physician Management of blood pressure, Withings Smart Blood Pressure Monitor; Other · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: TX000045- Dose A, TX000045- Dose B, Placebo; Drug
Lead sponsor: Tectonic Therapeutic; Industry
Eligibility: 18 Years to 83 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more

Conditions: Pulmonary Hypertension
Interventions: BQ-123; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Intracerebral Hemorrhage, Stroke, Hypertension
Interventions: Blood pressure management policies; Other
Lead sponsor: The George Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Interventions: Iloprost, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Hyperlipidemia, Hypertension, Cardiovascular Disease
Interventions: CVRS Intervention; Behavioral
Lead sponsor: Korey Kennelty; Other
Eligibility: 55 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 18
States / cities: Gainesville, Florida • Tampa, Florida • Pocatello, Idaho + 14 more

Conditions: Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer, Obstetric Procedure Pain, Orthopedic Procedure Pain, Post-Dural Puncture Headache
Interventions: Tactile Imaging (VerTouch), Control (palpation); Device · Other
Lead sponsor: IntuiTap Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Providence, Rhode Island • Charleston, South Carolina • Houston, Texas

Conditions: Hypertension Secondary
Interventions: Intensive Clinic Management (ICM), Intensive tailored telehealth management (ITTM); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 80 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Glaucoma
Interventions: Baerveldt Glaucoma Implant 350-mm2 / BG101-350, Transscleral Diode Laser Cyclophotocoagulation, Ahmed Model FP7 Flexible Plate, Baerveldt Glaucoma Implant 250-mm2 / BG103-250; Device · Procedure
Lead sponsor: Robert Feldman; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 18 more

Search by objective public record fields.

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Effects of Head Elevation on Intracranial Pressure in Children

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study

Ahmed Glaucoma Valve Surgery With Mitomycin-C

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Feasibility of Home Telehealth Monitoring for Improvement in Management of Hypertension for Secondary Stroke Prevention

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

The Role of Endothelin in Pulmonary Hypertension

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

MEDication Focused Outpatient Care for Underutilization of Secondary Prevention

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

Telehealth-Enhanced Assessment and Management After Stroke-Blood Pressure

Observational Study of Cortical Spreading Depression in Human Brain Trauma

The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)